NCT03562156 - A Study of Oral Oteseconazole for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection) | Biotech Hunter

Enrollment

438

Participants

Timeline

Start Date

August 16, 2018

Primary Completion Date

October 19, 2020

Study Completion Date

August 6, 2021

Conditions

Recurrent Vulvovaginal Candidiasis

Interventions

DRUG

Oteseconazole (VT-1161)

Oteseconazole (VT-1161) 150mg capsule

DRUG

Placebo

matching placebo capsule

Trial Locations (25)

11777

31142, Port Jefferson

14224

31127, West Seneca

19102

31134, Philadelphia

23225

31113, Richmond

27103

31145, Winston-Salem

27408

31132, Greensboro

27607

31144, Raleigh

28557

31116, Morehead City

30095

31111, Norcross

33319

31139, Lauderdale Lakes

33414

31106, Wellington

34239

31143, Sarasota

35233

31123, Birmingham

37620

31120, Bristol

45005

31125, Franklin

70001

31107, Metairie

70006

31105, Metairie

70433

31146, Covington

77054

31102, Houston

84020

31117, Draper

89123

31118, Las Vegas

89128

31103, Las Vegas

92111

31108, San Diego

02720

31147, Fall River

08648

31114, Lawrenceville